Valuation: MYOS Corp

Market Cap 7.25M 6.47M 6.04M 5.49M 10.33M 701M 10.41M 72.59M 28.36M 357M 27.2M 26.62M 1.15B P/E 2021
-1.04x
P/E 2022 -0.41x
Enterprise Value 2.88M 2.57M 2.4M 2.18M 4.1M 278M 4.13M 28.82M 11.26M 142M 10.8M 10.57M 455M EV / Sales 2021
1.74x
EV / Sales 2022 0.46x
Free-Float
-
Yield 2021 *
-
Yield 2022 -

Financials

2021 2022
Net sales 22.13M 19.77M 18.45M 16.76M 31.56M 2.14B 31.79M 222M 86.6M 1.09B 83.08M 81.28M 3.5B 43.11M 38.52M 35.94M 32.64M 61.48M 4.17B 61.93M 432M 169M 2.12B 162M 158M 6.82B
Net income -43.82M -39.15M -36.52M -33.18M -62.48M -4.24B -62.95M -439M -171M -2.16B -164M -161M -6.93B -47.62M -42.54M -39.69M -36.05M -67.9M -4.61B -68.41M -477M -186M -2.34B -179M -175M -7.53B
Net Debt -7.44M -6.65M -6.2M -5.63M -10.61M -720M -10.69M -74.55M -29.13M -366M -27.94M -27.33M -1.18B -4.37M -3.9M -3.64M -3.31M -6.23M -423M -6.28M -43.77M -17.1M -215M -16.4M -16.05M -691M
Logo MYOS Corp
MYOS RENS Technology Inc. is focused on the discovery, development and commercialization of nutritional ingredients, functional foods, and other technologies for maintaining or improving the health and performance of muscle tissue. Its research is focused on developing strategies and therapeutic interventions to address muscle-related conditions, including sarcopenia, cachexia, and inherited and acquired muscle diseases. The Company, through its subsidiary, holds the intellectual property pertaining to Fortetropin, which is a dietary supplement that has been shown in clinical studies to temporarily decrease the levels of serum myostatin, MYO-T12, a formulation containing Fortetropin. Fortetropin is the Company's all-natural food ingredient clinically shown to enhance muscle size, lean body mass and strength as part of resistance training in humans. Fortetropin is made from fertilized chicken egg yolks using a process that retains the biological integrity and bioactivity of the product.
Employees
-
Sector
-